Next Article in Journal
Viruses Challenge Selectivity Barrier of Nuclear Pores
Previous Article in Journal
Sequence Heterogeneity of the ORF3 Gene of Porcine Epidemic Diarrhea Viruses Field Samples in Fujian, China, 2010–2012
Viruses 2013, 5(10), 2384-2409; doi:10.3390/v5102384

Vaccines in Development against West Nile Virus

*  and
Received: 21 August 2013 / Revised: 21 September 2013 / Accepted: 26 September 2013 / Published: 30 September 2013
(This article belongs to the Section Antivirals & Vaccines)
View Full-Text   |   Download PDF [676 KB, uploaded 30 September 2013]   |   Browse Figures
Abstract: West Nile encephalitis emerged in 1999 in the United States, then rapidly spread through the North American continent causing severe disease in human and horses. Since then, outbreaks appeared in Europe, and in 2012, the United States experienced a new severe outbreak reporting a total of 5,387 cases of West Nile virus (WNV) disease in humans, including 243 deaths. So far, no human vaccine is available to control new WNV outbreaks and to avoid worldwide spreading. In this review, we discuss the state-of-the-art of West Nile vaccine development and the potential of a novel safe and effective approach based on recombinant live attenuated measles virus (MV) vaccine. MV vaccine is a live attenuated negative-stranded RNA virus proven as one of the safest, most stable and effective human vaccines. We previously described a vector derived from the Schwarz MV vaccine strain that stably expresses antigens from emerging arboviruses, such as dengue, West Nile or chikungunya viruses, and is strongly immunogenic in animal models, even in the presence of MV pre-existing immunity. A single administration of a recombinant MV vaccine expressing the secreted form of WNV envelope glycoprotein elicited protective immunity in mice and non-human primates as early as two weeks after immunization, indicating its potential as a human vaccine.
Keywords: West Nile vaccine; West Nile virus; measles vaccine; recombinant live attenuated vaccine; flavivirus West Nile vaccine; West Nile virus; measles vaccine; recombinant live attenuated vaccine; flavivirus
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Brandler, S.; Tangy, F. Vaccines in Development against West Nile Virus. Viruses 2013, 5, 2384-2409.

AMA Style

Brandler S, Tangy F. Vaccines in Development against West Nile Virus. Viruses. 2013; 5(10):2384-2409.

Chicago/Turabian Style

Brandler, Samantha; Tangy, Frederic. 2013. "Vaccines in Development against West Nile Virus." Viruses 5, no. 10: 2384-2409.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert